Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dawn Goodyear

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Thrombosis Research|September 25, 2020
Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, CanadaChris Wynick, Joanne Britto, Daniel Sawler, et al.
Thrombosis Research|April 9, 2023
Geographic disparities in the care and outcomes in adult chronic immune thrombocytopeniaErika Wall, John Podstawka, Jeffery M Patterson, et al.
Thrombosis Research|October 18, 2022
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort studyJohn Podstawka, Erika Wall, Lauren Bolster, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2026
Venous Thromboembolism Prophylaxis and Postoperative Outcomes in Persons with Bleeding Disorders Undergoing Major Surgery: A Canadian Pilot Feasibility StudyKelsey Uminski, Hao Wei Sun, Dawn Goodyear, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 15, 2026
Optimizing Emergency Department Care for People With Bleeding Disorders: A Scoping Review of Barriers and Interventions for ImprovementLing-Yi Guo, Diane L Lorenzetti, Natalia Rydz, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|January 22, 2026
Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER studyStephen D Betschel, Hugo Chapdelaine, Remi Gagnon, et al.
Journal of Clinical Medicine|December 11, 2022
Hypercoagulability and Inflammatory Markers in a Case of Congenital Thrombotic Thrombocytopenic Purpura Complicated by Fetal DemiseLeslie Skeith, Kelle Hurd, Shruti Chaturvedi, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|September 28, 2024
Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in CanadaAdil Adatia, Jean-Nicolas Boursiquot, Dawn Goodyear, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|March 20, 2025
Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey studyPaul K Keith, Gina Lacuesta, Dawn Goodyear, et al.
Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)|October 2, 2025
[Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE]Inmaculada Martinez-Saguer, Andrea Zanichelli, Emel Aygören-Pürsün, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Thrombosis Research|September 25, 2020
Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, CanadaChris Wynick, Joanne Britto, Daniel Sawler, et al.
Thrombosis Research|April 9, 2023
Geographic disparities in the care and outcomes in adult chronic immune thrombocytopeniaErika Wall, John Podstawka, Jeffery M Patterson, et al.
Thrombosis Research|October 18, 2022
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort studyJohn Podstawka, Erika Wall, Lauren Bolster, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2026
Venous Thromboembolism Prophylaxis and Postoperative Outcomes in Persons with Bleeding Disorders Undergoing Major Surgery: A Canadian Pilot Feasibility StudyKelsey Uminski, Hao Wei Sun, Dawn Goodyear, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 15, 2026
Optimizing Emergency Department Care for People With Bleeding Disorders: A Scoping Review of Barriers and Interventions for ImprovementLing-Yi Guo, Diane L Lorenzetti, Natalia Rydz, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|January 22, 2026
Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER studyStephen D Betschel, Hugo Chapdelaine, Remi Gagnon, et al.
Journal of Clinical Medicine|December 11, 2022
Hypercoagulability and Inflammatory Markers in a Case of Congenital Thrombotic Thrombocytopenic Purpura Complicated by Fetal DemiseLeslie Skeith, Kelle Hurd, Shruti Chaturvedi, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|September 28, 2024
Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in CanadaAdil Adatia, Jean-Nicolas Boursiquot, Dawn Goodyear, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|March 20, 2025
Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey studyPaul K Keith, Gina Lacuesta, Dawn Goodyear, et al.
Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)|October 2, 2025
[Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE]Inmaculada Martinez-Saguer, Andrea Zanichelli, Emel Aygören-Pürsün, et al.
Pageof 4